NAS:SGEN (USA) Also trade in: Germany

Seattle Genetics Inc

$ 70.64 -1.1 (-1.53%)
Volume: 606,080 Avg Vol (1m): 695,053
Market Cap $: 11.40 Bil Enterprise Value $: 10.98 Bil
P/E (TTM): 0.00 P/B: 8.65
Earnings Power Value -7.94
Net Current Asset Value 2.49
Tangible Book 4.6
Projected FCF -1.55
Median P/S Value 77.97
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 9/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt No Debt
Cash-To-Debt ranked higher than
98.14% of 1078 companies
in the Biotechnology industry.
Industry Max: 20856.43, Med: 64.02, Min: 0.01
SGEN: No Debt
Ranked among companies with meaningful Cash-To-Debt only.
N/A
Equity-to-Asset 0.83
Equity-to-Asset ranked higher than
81.52% of 763 companies
in the Biotechnology industry.
Industry Max: 3.47, Med: 0.69, Min: -9.46
SGEN: 0.83
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: 0.36, Med: 0.76, Max: 0.96
Current: 0.83
0.36
0.96
Interest Coverage No Debt
Interest Coverage ranked higher than
98.00% of 500 companies
in the Biotechnology industry.
Industry Max: 22756408, Med: 10000, Min: 0.12
SGEN: No Debt
Ranked among companies with meaningful Interest Coverage only.
N/A
Piotroski F-Score 3
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 24.19
DISTRESS
GREY
SAFE
Beneish M-Score -2.46
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC -24.57%
WACC 13.95%

Profitability & Growth : 4/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % -30.99
Operating Margin ranked higher than
59.97% of 792 companies
in the Biotechnology industry.
Industry Max: 46829238.82, Med: -113.97, Min: -1969600
SGEN: -30.99
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: -163.3, Med: -37.81, Max: -23.35
Current: -30.99
-163.3
-23.35
Net Margin % -17.53
Net Margin ranked higher than
68.56% of 792 companies
in the Biotechnology industry.
Industry Max: 49899604.52, Med: -111.91, Min: -2150400
SGEN: -17.53
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: -160.41, Med: -33.76, Max: -17.53
Current: -17.53
-160.41
-17.53
ROE % -9.40
ROE ranked higher than
73.91% of 989 companies
in the Biotechnology industry.
Industry Max: 326.78, Med: -42.82, Min: -100794.12
SGEN: -9.4
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: -79.94, Med: -27.14, Max: -9.4
Current: -9.4
-79.94
-9.4
ROA % -8.05
ROA ranked higher than
75.37% of 1084 companies
in the Biotechnology industry.
Industry Max: 224.74, Med: -34.77, Min: -3751.92
SGEN: -8.05
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -40.26, Med: -16.99, Max: -8.05
Current: -8.05
-40.26
-8.05
ROC (Joel Greenblatt) % -137.57
ROC (Joel Greenblatt) ranked higher than
63.51% of 1036 companies
in the Biotechnology industry.
Industry Max: 641137.84, Med: -521.46, Min: -3427023.81
SGEN: -137.57
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -903.49, Med: -253.26, Max: -137.57
Current: -137.57
-903.49
-137.57
3-Year Total Revenue Growth Rate 24.80
3-Year Revenue Growth Rate ranked higher than
69.59% of 651 companies
in the Biotechnology industry.
Industry Max: 906.3, Med: 1.1, Min: -100
SGEN: 16.8
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
3-Year Revenue Growth Rate range over the past 10 years
Min: 7.7, Med: 28.65, Max: 148.1
Current: 16.8
7.7
148.1
3-Year Total EBITDA Growth Rate -30.00
3-Year EBITDA Growth Rate ranked lower than
80.05% of 802 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 4.6, Min: -2038.5
SGEN: -21.7
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
3-Year EBITDA Growth Rate range over the past 10 years
Min: -31.6, Med: -4.25, Max: 30.1
Current: -21.7
-31.6
30.1
3-Year EPS w/o NRI Growth Rate -14.90
3-Year EPS w/o NRI Growth Rate ranked lower than
68.28% of 763 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 5.7, Min: -2103.4
SGEN: -14.9
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: -27.9, Med: -3.6, Max: 34
Current: -14.9
-27.9
34

» SGEN's 30-Y Financials

Financials (Next Earnings Date: 2019-07-26)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:SGEN

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325414    SIC : 2836
Compare OCSE:GEN HKSE:02269 HKSE:01177 NAS:IONS NAS:SAGE NAS:SRPT OCSE:NZYM B NAS:JAZZ XBRU:UCB HKSE:06160 NAS:TECH NAS:ALNY SZSE:000661 NAS:NBIX NAS:MRNA NAS:BLUE XAMS:GLPG NAS:BMRN NAS:EXEL NAS:ASND
Traded in other countries SGT.Germany
Address 21823 - 30th Drive South East, Building 3, Bothell, WA, USA, 98021
Seattle Genetics is a biotech firm focused on the development of monoclonal antibody-based therapies. The company's lead product, Adcetris, has received approval for relapsed/refractory and post-consolidation Hodgkin lymphoma, anaplastic large-cell lymphoma, and two other subtypes of cutaneous T-cell lymphoma. The company has several other early-stage programs in trials. Seattle Genetics also licenses its antibody-drug conjugate technology to a number of leading biotechnology and pharmaceutical companies.

Ratios

Current vs industry vs history
PB Ratio 8.65
PB Ratio ranked lower than
75.26% of 962 companies
in the Biotechnology industry.
Industry Max: 2236, Med: 4.1, Min: 0.05
SGEN: 8.65
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 4.23, Med: 9.83, Max: 35.99
Current: 8.65
4.23
35.99
PS Ratio 16.03
PS Ratio ranked lower than
60.74% of 726 companies
in the Biotechnology industry.
Industry Max: 113071.43, Med: 9999, Min: 0.01
SGEN: 16.03
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 10.06, Med: 17.68, Max: 45.33
Current: 16.03
10.06
45.33
EV-to-EBIT -49.95
EV-to-EBIT ranked lower than
100.00% of 261 companies
in the Biotechnology industry.
Industry Max: 4391.42, Med: 22.17, Min: 0.02
SGEN: -49.95
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -102.6, Med: -38.55, Max: -4.7
Current: -49.95
-102.6
-4.7
EV-to-EBITDA -56.80
EV-to-EBITDA ranked lower than
100.00% of 281 companies
in the Biotechnology industry.
Industry Max: 28816.43, Med: 18.08, Min: 0.02
SGEN: -56.8
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -120.2, Med: -43.4, Max: -4.9
Current: -56.8
-120.2
-4.9
EV-to-Revenue 15.47
EV-to-Revenue ranked lower than
56.68% of 771 companies
in the Biotechnology industry.
Industry Max: 118933, Med: 13.69, Min: 0.05
SGEN: 15.47
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: 7.4, Med: 16, Max: 40.4
Current: 15.47
7.4
40.4
Current Ratio 3.27
Current Ratio ranked lower than
55.31% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.46, Min: 0.01
SGEN: 3.27
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 2.65, Med: 4.95, Max: 30.03
Current: 3.27
2.65
30.03
Quick Ratio 2.95
Quick Ratio ranked lower than
55.96% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.18, Min: 0.01
SGEN: 2.95
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 2.29, Med: 4.62, Max: 30.03
Current: 2.95
2.29
30.03
Days Inventory 298.22
Days Inventory ranked lower than
89.19% of 481 companies
in the Biotechnology industry.
Industry Max: 908.49, Med: 125.55, Min: 0.02
SGEN: 298.22
Ranked among companies with meaningful Days Inventory only.
Days Inventory range over the past 10 years
Min: 234.02, Med: 514.46, Max: 639.76
Current: 298.22
234.02
639.76
Days Sales Outstanding 80.77
Days Sales Outstanding ranked lower than
73.20% of 668 companies
in the Biotechnology industry.
Industry Max: 1096.56, Med: 64.17, Min: 0.06
SGEN: 80.77
Ranked among companies with meaningful Days Sales Outstanding only.
Days Sales Outstanding range over the past 10 years
Min: 40, Med: 61.03, Max: 562.77
Current: 80.77
40
562.77
Days Payable 170.80
Days Payable ranked lower than
100.00% of 536 companies
in the Biotechnology industry.
Industry Max: 1651.36, Med: 63.91, Min: 0.12
SGEN: 170.8
Ranked among companies with meaningful Days Payable only.
Days Payable range over the past 10 years
Min: 170.8, Med: 224.03, Max: 1833.79
Current: 170.8
170.8
1833.79

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -4.70
3-Year Share Buyback Rate ranked higher than
75.50% of 857 companies
in the Biotechnology industry.
Industry Max: 43.5, Med: -13.4, Min: -1815.4
SGEN: -4.7
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -113.5, Med: -11.05, Max: -2.2
Current: -4.7
-113.5
-2.2

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 15.36
Price-to-Tangible-Book ranked lower than
80.87% of 894 companies
in the Biotechnology industry.
Industry Max: 800, Med: 5.32, Min: 0.05
SGEN: 15.36
Ranked among companies with meaningful Price-to-Tangible-Book only.
Price-to-Tangible-Book range over the past 10 years
Min: 1.78, Med: 8.29, Max: 33.75
Current: 15.36
1.78
33.75
Price-to-Median-PS-Value 0.91
Price-to-Median-PS-Value ranked lower than
58.85% of 678 companies
in the Biotechnology industry.
Industry Max: 126.94, Med: 0.92, Min: 0.01
SGEN: 0.91
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.59, Med: 1.15, Max: 100
Current: 0.91
0.59
100
Earnings Yield (Joel Greenblatt) % -2.00
Earnings Yield (Greenblatt) ranked higher than
69.66% of 1081 companies
in the Biotechnology industry.
Industry Max: 5000, Med: -7.73, Min: -10000
SGEN: -2
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -21.4, Med: -2.6, Max: -1
Current: -2
-21.4
-1

More Statistics

Revenue (TTM) (Mil) $ 709.31
EPS (TTM) $ -0.78
Beta 1.99
Volatility % 51.63
52-Week Range $ 50.71 - 84.37
Shares Outstanding (Mil) 161.31

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 3
Positive ROA N
Positive CFROA N
Higher ROA yoy Y
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy N
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy N